Floatz logo

Ancrod

Brain Infarction

Neurobiological Technologiesprotein_peptidePhase 3Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Brain Infarction cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Recombinant Human Plasminogen Activator
Nippon Medical School
Phase 4BB
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB
WARFARIN
Assistance Publique - Hôpitaux de Paris
Phase 3BB
Recombinant Human Plasminogen Activator
Nippon Medical School
Phase 4BB

View all 14 →

Same molecule, other indications

Ancrod is also rated in:

brain ischemiaDormant
CC
Indicative ·
43 / 100
View asset →
stroke disorderDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →